Premium
Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation
Author(s) -
Latruffe Norbert,
Lançon Allan,
Frazzi Raffaele,
Aires Virginie,
Delmas Dominique,
Michaille JeanJacques,
Djouadi Fatima,
Bastin Jean,
CherkaouiMalki Mustapha
Publication year - 2015
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12819
Subject(s) - resveratrol , proinflammatory cytokine , inflammation , microrna , chemokine , immunology , cancer research , biology , medicine , pharmacology , gene , genetics
This review presents recent evidence implicating microRNAs (miRNAs) in the beneficial effects of resveratrol (trihydroxystilbene), a nonflavonoid plant polyphenol, with emphasis on its anti‐inflammatory effects. Many diseases and pathologies have been linked, directly or indirectly, to inflammation. These include infections, injuries, atherosclerosis, diabetes mellitus, obesity, cancer, osteoarthritis, age‐related macular degeneration, demyelination, and neurodegenerative diseases. Resveratrol can both decrease the secretion of proinflammatory cytokines (e.g., IL‐6, IL‐8, and TNF‐α) and increase the production of anti‐inflammatory cytokines; it also decreases the expression of adhesion proteins (e.g., ICAM‐1) and leukocyte chemoattractants (e.g., MCP‐1). Resveratrol's primary targets appear to be the transcription factors AP‐1 and NF‐κB, as well as the gene COX2 . Although no mechanistic link between any particular miRNA and resveratrol has been identified, resveratrol effects depend at least in part upon the modification of the expression of a variety of miRNAs that can be anti‐inflammatory (e.g., miR‐663), proinflammatory (e.g., miR‐155), tumor suppressing (e.g., miR‐663), or oncogenic (e.g., miR‐21).